Article Information
History
- December 4, 2020.
Article Versions
- Version 1 (December 2, 2020 - 19:10).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Annika Roth1,#,
- Steffen Lütke2,3,#,
- Denise Meinberger1,
- Gabriele Hermes1,
- Gerhard Sengle2,3,
- Manuel Koch2,4,5,
- Thomas Streichert1 and
- Andreas R. Klatt1,*
- 1Institute for Clinical Chemistry, Medical Faculty, University of Cologne, 50937 Cologne, Germany
- 2Institute for Biochemistry II, Medical Faculty, University of Cologne, 50931 Cologne, Germany
- 3Clinic for Pediatric and Adolescent Medicine, Medical Faculty, University of Cologne, 50937 Cologne, Germany
- 4Institute for Dental Research and Oral Musculoskeletal Biology, Medical Faculty, University of Cologne, 50931 Cologne, Germany
- 5Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany
- ↵*Correspondence should be addressed to: Prof. Dr. Andreas R. Klatt, Institut für Klinische Chemie, Uniklinik Köln, Kerpener Strasse 62, 50937 Köln, Deutschland., Tel.: 0049-221-4785292; Fax: 0049-221-4781425291; E-mail: andreas.klatt{at}uk-koeln.de.
Posted December 04, 2020.
LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro
